Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Fig. 1

Anti-receptor-binding domain (RBD) SARS-CoV-2 IgG titers following BNT162b2 mRNA vaccination. All allo-HCT patients received the first vaccine on day 0 and 39 of the 40 patients received the second vaccine on day 21. a Comparison of Ab levels in staff members of nursing homes naive of SARS-CoV-2 infection (n = 40, gray bars) versus naive allo-HCT recipients (n = 37, white bars). b Comparison of Ab levels in healthy adults (n = 40, gray bars) versus in allo-HCT recipients naïve of COVID-19 without moderate/severe chronic GVHD and not given rituximab in the year before the first vaccination (n = 22, red bars), in naive allo-HCT recipients with moderate/severe chronic GVHD (n = 9, blue bars; please note that 8 and 5 patients had Ab levels < 5 IU/mL on days 21 and 49, respectively; this include 1 patient given rituximab within the year before the first vaccination), and in naive allo-HCT recipients without moderate/severe chronic GVHD and given rituximab within the year before the first vaccination (n = 6, green bars). The horizontal broken lines show the limit of possibly protective levels (200 IU/mL). *P value < 0.05; **P value < 0.01; ***P value < 0.001; ****P value < 0.0001. For b, black stars refer to comparisons with naive healthy adults, while red stars refer to comparisons to naive allo-HCT recipients without moderate/severe chronic GVHD and not given rituximab in the year before the first vaccination

Back to article page